Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study

Ítems similars

• Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
  per: Lampert, Erika J, et al.
  Publicat: (2020)
• A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer
  per: Gatti‐Mays, Margaret E., et al.
  Publicat: (2020)
• Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
  per: Brill, Ethan, et al.
  Publicat: (2017)
• Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8(+) T cells compared with women with BRCA wild-type disease during the early disease course
  per: Lee, Jung-Min, et al.
  Publicat: (2019)
• Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
  per: Lampert, Erika J., et al.
  Publicat: (2020)